

**Life Sciences Fund Amsterdam B.V.**

Financial statements for filing  
for the year 2023

## Table of contents

Limited balance sheet as at 31 december 2023	2
Notes	3

## Limited balance sheet as at 31 December 2023

<b>Assets</b>	31 December 2023	31 December 2022
(in euros)		
<b>Financial Fixed Assets</b>	8,172,027	7,278,797
<b>Current Assets</b>	81,766	928,463
	8,253,794	8,207,260

<b>Liabilities</b>	31 December 2023	31 December 2022
(in euros)		
<b>Equity</b>		
<i>Issued Capital</i>	198,908	198,908
<i>Share premium</i>	7,924,762	9,784,766
<i>Revaluation reserve</i>	5,699,979	5,699,979
<i>Accumulated losses</i>	(5,628,253)	(7,489,962)
	8,195,396	8,193,691
<b>Current liabilities</b>	58,398	13,569
	8,253,794	8,207,260

## **NOTES**

### **General**

Life Sciences Fund Amsterdam B.V. is an independent venture capital fund, founded on 3 February 2009. Its goal is to provide investment capital to fund biomedical entrepreneurial activity in the greater Amsterdam area.

The fund targets companies that are developing commercially promising products and technologies in life sciences, including: pharmaceuticals, biotechnology and other high technology opportunities that offer venture capital returns.

The fund focuses on seed and early stage companies, but also on pre-seed commercially viable academic projects. The benefits of this early funding mean that emerging medical breakthroughs in research and technology businesses can be sustained by sufficient venture capital to optimize their chances of success and ultimately provide revenue to the fund's investors and the research groups involved. Once these companies are established with seed funding, the fund will seek to work with other traditional venture capital companies to partner in the effort to advance these technologies.

The fund's office address is: Pietersbergweg 285, 1105BM Amsterdam.

The fund is registered at the Chamber of Commerce with number 32146281.

### **Estimates**

The preparation of financial statements in conformity with the relevant rules requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group's accounting policies. If necessary, for the purposes of providing the view required under Section 362, subsection 1, Book 2 of the Dutch Civil Code, the nature of these estimates and judgements, including the related assumptions, is disclosed in the notes to the financial statement items in question.

### **Consolidation principles**

Participations in which a majority interest is held, are not consolidated based on the exemption of article 2:407 part 1 BW (Dutch Civil Code). Participations are held to exit at a certain moment, which exit is typically defined by a concrete exit strategy.

### **Principles of accounting**

The accompanying financial statements have been prepared in accordance with the statutory provisions of Part 9, Book 2 of the Dutch Civil Code and the firm pronouncements in the Guidelines for Annual Reporting in the Netherlands as issued by the Dutch Accounting Standards Board.

In general, assets and liabilities are stated at the amounts at which they were acquired or incurred, or current value. The financial statements are presented in euro.

### **Foreign exchange translation**

Other assets and liabilities, denominated in foreign currency, are translated into Euros at the exchange rates on balance sheet date.

Any results from foreign currency translation are included in the profit and loss account except for fixed assets related transactions.

### ***Financial fixed assets***

#### ***Participations***

The participations, that are held for trading, are stated at fair value according to the latest International Private Equity and Venture Capital Valuation Guidelines (IPEV Valuation Guidelines). In the first period after the investment has taken place this value is in most cases the historical cost. In due course this value will be adjusted fair value including liquidation preferences given to preferred shareholders. Changes in the fair value are recognized directly in the income statement. The fair value is based on the following principles:

- Stock quote on balance sheet date if publicly traded;
- Price paid by third party in new financing round;
- Valuation prepared by independent professional third party;
- Estimated future result is significantly lower than the previously expected performance, leading to a permanent decrease in value.

The formal and / or practical restrictions concerning the tradability are taken into account if necessary.

#### ***Loans***

Other receivables disclosed under financial assets include issued loans and are initially measured at fair value and subsequently carried at amortized cost.

### ***Receivables***

Receivables are recognized initially at fair value and subsequently measured at amortized cost. Provision for uncollectible, is credited against receivables.

### ***Cash and cash equivalents***

Cash and cash equivalents include cash in hand and bank balances. Bank overdrafts are shown within borrowings in current liabilities on the balance sheet. Cash and cash equivalents are stated at face value.

### ***Liabilities***

Borrowings are initially recognized at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortized cost, being the amount received taking account of any premium or discount, less transaction costs.

### ***Other assets and liabilities***

In general, assets and liabilities are stated at the amounts at which they were acquired or incurred, or current value. If not specifically stated otherwise, they are recognized at the amounts at which they were acquired or incurred.

### ***Results***

Income and expenses are allocated to the financial year to which they relate, except dividend and supervisory board remuneration from investments, which are allocated to the year they are made payable.

Income and expenses are allocated to the financial year they relate to. Expenses are based on the historical cost convention. All amounts are in euros, unless otherwise stated.

***Interest paid and received***

Interest paid and received is recognized on a time-weighted basis, taking account of the effective interest rate of the assets and liabilities concerned.

***Taxes***

Taxes are calculated on the result, taking into account existing tax facilities (including losses carried forward, and exempt items and non-deductible expense).

No deferred tax debit caused by fiscal compensable tax losses will be capitalized as long no (fiscal) profits are to be expected.

## Limited balance sheet as at 31 December 2023

### *Financial fixed assets*

	2023	2022
	€	€
Book value as at 1 January	7,278,797	7,278,097
Investments	80,000	-
Revaluation	892,397	700
Impairment	(79,167)	-
Changes in book value	893,230	700
Book value as at 31 December	8,172,027	7,278,797

### *Participations in which Life Sciences Fund Amsterdam B.V. holds an interest of more than 20%:*

	Interest
Sigmascreening B.V., Amsterdam, The Netherlands	38,40%
Regenesance B.V., Amsterdam, The Netherlands	33,61%
ACS Biomarker B.V., Amsterdam, The Netherlands	25,93%
Caelus Pharmaceuticals B.V., The Netherlands	28,73%

### *Current assets*

All current assets are receivable within 1 year.

**Shareholders' equity**

(in euros)	Issued Capital	Share premium common shares	Share premium preferred shares	Revaluation reserve	Accumulated losses	Total
Balance 31 December 2021	198,908	88,887	9,695,879	8,088,375	(10,777,636)	7,294,413
Changes during the year:						
Realisation revaluation	-	-	-	(2,388,396)	2,388,396	
Profit (loss) for the year	-	-	-	-	899,278	899,278
Balance 31 December 2022	198,908	88,887	9,695,879	5,699,979	(7,489,962)	8,193,691
Changes during the year:						
Realisation revaluation	-	-	-	-	-	-
Distribution of dividend	-	-	(1,860,004)	-	-	(1,860,004)
Profit (loss) for the year	-	-	-	-	1,861,709	1,861,709
Balance 31 December 2023	198,908	88,887	7,835,875	5,699,979	(5,628,253)	8,195,396

**Issued capital**

The authorized capital of the Life Sciences Fund Amsterdam B.V. amounts to € 450,000 divided into 225,000 common shares with a par value of € 1.00 and 22,500,000 preferred shares with a par value of € 0.01.

The issued and fully paid-up capital consists of 100.072 common shares and 9.883.601 preferred shares.

**Share premium**

The share premium consists of the proceeds of issuance of shares over and above their nominal value.

**Current liabilities**

All current liabilities are due within 1 year.

**Employees**

The company has no employees.

**Contingent liabilities**

There are no contingent liabilities.

Amsterdam, 16 May 2024

Seed Fund Management B.V